Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Study breakdownUpdated 11 min read

Epitalon human studies: what the small cohorts actually measured

Most epitalon human data come from one group and used the pineal extract Epithalamin, not synthetic epitalon. What each study measured, the claimed benefits versus the evidence, and side effects.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer: the human evidence for epitalon is thin and mostly indirect. The larger human studies come from the St. Petersburg group that developed it, most of them used Epithalamin, the bovine pineal gland extract that epitalon was modeled on, and none is an independent, placebo-controlled trial of synthetic epitalon. [3] [4] Two Russian studies did give synthetic epitalon to people and reported higher melatonin output, but their abstracts do not state the study design or the sample size. [18] [19] The telomerase finding that drives most interest in epitalon comes from cells in a dish, not from people. [9]

This page lists what each human study measured, sets the claimed benefits against that evidence, then covers the melatonin and telomerase claims, the forms sold, side effects, the cancer question, and legal status. It does not give dosing; none has been established for synthetic epitalon in people.

Has epitalon been tested in humans?

Epitalon is the four amino acid peptide Ala-Glu-Asp-Gly. It was synthesized based on the amino acid composition of Epithalamin, and was later identified in the pineal gland's own peptide complex. [11] That history matters, because "epitalon human studies" often cite Epithalamin trials.

1. Elderly patients, Epithalamin and Thymalin, 2003. This is the trial most often cited for epitalon. PubMed tags it as a randomized controlled trial, and the paper describes it as randomized and placebo controlled: 152 elderly people were divided by stratified randomization into placebo (48), Thymalin (58), and Epithalamin (46) groups and given six courses over 3 years. Eight-year mortality was 13.6% with placebo, 6.6% with Thymalin, and 8.5% with Epithalamin; the abstract reports 266 people followed for 6 to 8 years. Reporting is sparse, the trial comes from the developing institute, and it has never been independently replicated. It tested the pineal extract Epithalamin, not synthetic epitalon, so it is not an epitalon trial. [3]

2. Coronary patients with accelerated aging, Epithalamin, 2006 and 2011. A study at the Institute of Gerontology in Kyiv, co-authored by the developer, is described by its authors as randomized. The 2011 report gives 39 coronary patients Epithalamin courses on top of basic therapy and 40 basic therapy alone; the control group received no placebo. The authors report slower cardiovascular aging, better exercise tolerance, normalized melatonin rhythm, and lower mortality, including 28% fewer deaths at 12 years. [4] [5] The two papers appear to describe the same cohort at different follow-up points.

3. Melatonin rhythm, Epithalamin, 2004. Healthy older adults had night-time melatonin measured before and after a course of Epithalamin. [6] The results are covered below.

4. Retinitis pigmentosa, synthetic epitalon, 2002. The developers reported a positive clinical effect in 90% of patients with degenerative retinal disease, alongside rat data. The abstract describes no control group. [7]

5. Cells from older adults, synthetic epitalon, 2003. Lymphocytes taken from people aged 76 to 80 and treated with epitalon in culture showed activation of chromatin and ribosomal genes. [8] This used human cells in the laboratory; nobody was given epitalon.

6. Melatonin rhythm, Epithalamin and synthetic epitalon, 2007. In elderly people with low pineal function, both the extract and synthetic epitalon were reported to raise night melatonin, with no side effects reported. The abstract does not state the design, the sample size, or whether participants were randomized. [18]

7. Melatonin and clock genes, synthetic epitalon, 2020. The peptide, named by its sequence AEDG, was reported to raise urinary 6-sulfatoxymelatonin 1.7-fold in middle-aged people and to shift the expression of three clock genes in blood cells. Again the abstract gives no design or sample size. [19]

Taken together: the controlled human data are for Epithalamin, not synthetic epitalon. They are one sparsely reported randomized, placebo controlled trial in elderly people and one group of coronary patients treated without a placebo, both from researchers connected to the product. Synthetic epitalon itself has two human studies that reported higher melatonin output without stating their design or sample size, plus an uncontrolled report in retinal disease. That is why we grade epitalon as human observational evidence: under our methodology, the grade describes how the evidence was gathered, not how well epitalon works.

What are the claimed benefits of epitalon, and what does the evidence show?

Epitalon is marketed mainly for longer life, longer telomeres, better sleep, and protection against cancer. Each claim traces back to a different kind of evidence, and none rests on a controlled trial of synthetic epitalon in people.

  • Longer life. In female mice given epitalon for life, the longest-lived 10% lived longer, but mean life span did not change significantly. [12] The human mortality figures often quoted come from the 2003 trial of the extract Epithalamin, not epitalon. [3] Evidence in people: none for epitalon itself.
  • Longer telomeres. Epitalon switched on telomerase and lengthened telomeres in cultured human cells, and a 2025 study from a different group repeated the finding in several cell lines. [9] [10] Evidence in people: none; no study has measured telomere length before and after epitalon.
  • Better sleep and melatonin. Two Russian studies reported higher melatonin output after synthetic epitalon, but their abstracts do not state the design, the sample size, or whether participants were randomized. [18] [19] Evidence in people: a reported melatonin signal; sleep itself has not been measured.
  • Cancer protection. In mice, epitalon reduced leukemia in one study and malignant tumors in another. [12] [13] Evidence in people: none, and telomerase activation also raises a theoretical concern, covered below.
  • Eye health. The developers reported benefit in retinitis pigmentosa in a report with no described control group. [7] Evidence in people: one uncontrolled report.

The pattern is the same throughout: the strongest results are in cells and mice, and the human results are either for a different product, Epithalamin, or are small reports whose design is not stated.

Epitalon and telomerase: what the cell studies show

The claim that epitalon lengthens telomeres comes from a 2003 study in cultured human somatic cells, where epitalon switched on the catalytic subunit of telomerase, increased telomerase activity, and lengthened telomeres. [9] A 2025 study from a different group found telomere lengthening in several human cell lines, through telomerase in some lines and through a separate mechanism, alternative lengthening of telomeres, in others. [10]

Independent replication in cells is useful. But no study has measured telomere length in people before and after epitalon, and cell results often fail to carry over to whole organisms.

Epitalon and melatonin

The melatonin claim started with Epithalamin. In healthy older adults, night-time melatonin rose after treatment in people whose pineal function was low at baseline, and tended to fall in people whose function was normal. [6] The authors described this as a modulating effect rather than a simple increase. Two later Russian studies reported the same direction for synthetic epitalon: higher night melatonin in elderly people with low pineal function, and a 1.7-fold rise in a urinary melatonin marker in middle-aged people. [18] [19] Neither abstract states the design, the sample size, or whether participants were randomized, and both come from the network that developed the peptide, so they are a reported signal, not a confirmed effect. A 2025 review lists a direct influence on melatonin synthesis among epitalon's reported effects. [11] Whether synthetic epitalon changes sleep in people has not been tested; the sleep condition page covers options that have.

What the animal studies found

In female mice given epitalon from 3 months of age until death, the peptide slowed some aging biomarkers and extended the life span of the longest-lived 10% of animals, but did not significantly change mean life span. [12] That distinction is often lost in claims that epitalon "extends life." The longevity page compares it with other compounds studied for aging.

Epitalon nasal spray and capsules

The human reports describe treatment courses of the pineal preparations, and most research on synthetic epitalon has been done in cells and animals. [11] We found no published study measuring whether epitalon is absorbed from a nasal spray or capsule, so there is no evidence either form delivers the peptide. Quality is a separate concern: a Belgian medicines laboratory identified epitalon in two illegal pharmaceutical preparations. [14]

What are the side effects of epitalon?

No one has published a systematic study of epitalon's safety in people, so its side effects are unknown rather than absent. What the record contains:

  • The human reports. The authors of the 2007 melatonin study reported no side effects with either Epithalamin or synthetic epitalon, but the abstract does not state how many people took part or how side effects were tracked. [18] The other human studies of synthetic epitalon report no safety data in their abstracts. [7] [19]
  • Melatonin and sleep timing. The pineal preparation raised night melatonin in older adults whose levels were low and tended to lower it in those whose levels were normal. [6] If synthetic epitalon shifts melatonin rhythm as reported, sleep timing could change, and it has not been tested alongside melatonin supplements or sleep medicines. [18] [19]
  • The cancer question. Telomerase activation is the main theoretical concern, covered in the next section. [9]
  • Product quality. No regulator checks the identity or purity of epitalon sold for personal use, and a Belgian medicines laboratory has found it in illegal pharmaceutical preparations. [14] Reactions to an impure or mislabeled product would not show up in any study.

There are no data in pregnancy or breastfeeding. Anyone with a current or past cancer, or who takes medicines that affect sleep, should raise epitalon with a clinician.

Epitalon and cancer

The animal data point toward fewer tumors, not more. In one mouse study epitalon did not change total spontaneous tumor incidence but reduced leukemia; in another, treated mice had fewer malignant tumors and no metastases. [12] [13]

The theoretical concern is telomerase itself. Epitalon activates telomerase in human cells, and telomerase activity is also one way cancer cells keep dividing. [9] Mouse findings do not settle that question for people, and no long-term human safety study exists. Anyone with a current or past cancer should raise it with an oncologist.

What a convincing epitalon trial would look like

The gap between the claims and the evidence is easy to state. A trial that could move our grade would use synthetic epitalon of verified identity and purity, randomize participants to epitalon or a matching placebo, blind both participants and assessors, and be run or replicated by a group without a stake in the product. It would pre-register its outcomes, such as telomere length in blood cells, melatonin rhythm, or sleep, and report side effects. None of the studies above meets all of those conditions. The closest, the 2003 trial in elderly people, is described as randomized and placebo controlled, but it tested the extract Epithalamin, is sparsely reported, comes from the developing institute, and has never been replicated. [3] The Epithalamin study in coronary patients had no placebo and was co-authored by the developer. [5] Until such a trial exists, the telomerase and melatonin findings remain hypotheses about people rather than results in them.

Epitalon is often compared with other short peptides from its developers. Our pinealon vs epitalon comparison covers the three amino acid peptide from the same research program, which has only rat and cell data, and our epitalon vs thymalin comparison covers the thymus extract tested in a separate arm of the same 2003 trial.

Epitalon is not FDA approved. At the July 23 to 24, 2026 meeting of FDA's Pharmacy Compounding Advisory Committee, FDA presented epitalon for the 503A bulks list. [15] FDA's drug center recommended against listing it, and the advisory committee voted in favor. [1] It is not on that list, and FDA has proposed no rule. [16] On October 28, 2026, HHS released a draft enforcement discretion policy saying it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds single-ingredient epitalon by subcutaneous or intramuscular injection in intermittent courses, on a patient-specific prescription, when all of the policy's conditions are met. [1] That is not an FDA approval or a 503A bulks listing, it is not binding, and HHS may revisit it; the notice was published in the Federal Register on October 30, 2026. [2] Our explainer on the draft HHS policy covers its conditions and what did not change. Products labeled for research use are not lawful for human use. For tested athletes, it is prohibited under WADA's non-approved substances section. [17]

The epitalon regulatory timeline tracks its regulatory status, and the epitalon cost page explains why advertised prices are not a comparable figure.

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [20] [21] [22]

What that means for you

  • A pharmacy that compounds epitalon relies on HHS's draft policy, which has strict conditions and which HHS can revisit, so it carries some regulatory risk. Compounding it outside those conditions, such as in a blend or by another route, has no federal basis. [1]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [23]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [24]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [25] [26]

If you're going ahead anyway

Each step is on the epitalon page: check the pharmacy's license, what a legitimate prescription and consult look like, why this is safer than a research-use-only product, and questions to ask. These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [23]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Frequently asked questions

Has epitalon been tested in humans?

Yes, but thinly. Two Russian studies reported that synthetic epitalon raised melatonin output in people, and their abstracts do not state the study design or sample size. Most other human studies, including the randomized, placebo controlled 2003 trial often cited for epitalon, used Epithalamin, the bovine pineal extract epitalon was modeled on. No independent randomized, placebo-controlled trial of synthetic epitalon has been published. [3] [4] [11] [18] [19]

Does epitalon lengthen telomeres in people?

That has not been shown. Epitalon activated telomerase and lengthened telomeres in cultured human cells, and a 2025 study confirmed telomere lengthening in human cell lines. No study has measured telomere length in people before and after taking it. [9] [10]

Does epitalon raise melatonin?

Two Russian studies reported that it did. One found that both the extract Epithalamin and synthetic epitalon raised night melatonin in elderly people with low pineal function, and one found that the peptide raised a urinary melatonin marker 1.7-fold in middle-aged people. Neither abstract states the study design, the sample size, or whether participants were randomized, and both come from the network that developed the peptide, so this is a reported signal, not a confirmed effect. [6] [18] [19]

Does epitalon cause cancer?

No human data answer this. In mice, epitalon reduced spontaneous tumors. The theoretical concern comes from telomerase activation, which cancer cells also use, so long-term human safety data are needed before this can be settled. [9] [12] [13]

What are the claimed benefits of epitalon?

It is marketed for longer life, longer telomeres, better sleep, and cancer prevention. The telomere results come from cultured human cells, the life span and tumor results from mice, and the melatonin results from two Russian human studies of unstated design. The 2003 trial that reported lower mortality in elderly people tested the extract Epithalamin, not synthetic epitalon. None of these benefits has been shown in a controlled trial of epitalon in people. [3] [9] [12] [18] [19]

What are the side effects of epitalon?

No systematic human safety study has been published, so its side effects in people are unknown. The authors of one Russian melatonin study reported no side effects, without stating how many people took part. The main theoretical concern is that a telomerase activator could help existing cancer cells divide, although in mouse studies epitalon reduced leukemia and malignant tumors rather than increasing them. [9] [12] [13] [18]

Sources

Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.

  1. [1]HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendix A and Appendix B (draft, October 2026)2026
  2. [2]Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; Notice of availability (HHS Office of the Secretary, FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496, published October 30, 2026)Federal Register, 2026
  3. [3]Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003PubMed 14523363, 2003
  4. [4]Korkushko OV et al. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med 2006PubMed 17426848, 2006
  5. [5]Korkushko OV et al. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med 2011 (the treatment studied is the pineal preparation Epithalamin)PubMed 22451889, 2011
  6. [6]Korkushko OV et al. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people. Bull Exp Biol Med 2004PubMed 15452611, 2004
  7. [7]Khavinson V et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett 2002PubMed 12195242, 2002
  8. [8]Khavinson VK et al. Peptide Epitalon activates chromatin at the old age. Neuro Endocrinol Lett 2003PubMed 14647006, 2003
  9. [9]Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003PubMed 12937682, 2003
  10. [10]Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025PubMed 40908429, 2025

More from the blog